Skip to main content

ADVERTISEMENT

Anticoagulation

Original Contribution
10/15/2018

Nicola S. Vos, MD1;  Giovanni Amoroso, MD, PhD1;  Maarten A. Vink, MD, PhD1;  Moniek Maarse, MD2;  Rob Adams, MSc3;  Jean-Paul R. Herrman, MD, PhD1;  Mark S. Patterson, MD, PhD1;  Ren√® J. van der Schaaf, MD, PhD1;  Ton Slagboom, MD1;  Robbert J. de Winter, MD, PhD3

Nicola S. Vos, MD1;  Giovanni Amoroso...
Pretreatment with P2Y12 inhibitors before primary percutaneous coronary intervention can reduce the incidence of major adverse cardiovascular event rate in ST-segment elevation myocardial infarction patients. We investigated differences in...
Pretreatment with P2Y12 inhibitors before primary percutaneous coronary intervention can reduce the incidence of major adverse cardiovascular event rate in ST-segment elevation myocardial infarction patients. We investigated differences in...
Pretreatment with P2Y12...
10/15/2018
Journal of Invasive Cardiology
Original Contribution
10/23/2017

Pranoti G. Hiremath, MD1;  Kathleen Kearney, MD2;  Bryn Smith, MD2;  Creighton Don, MD2;  Danny Dvir, MD2;  Gabriel Aldea, MD2;  Mark Reisman, MD2;  James M. McCabe, MD2

Pranoti G. Hiremath, MD1;  Kathleen K...
Prosthetic leaflet thrombosis is a growing concern in transcatheter aortic valve replacement (TAVR). We analyzed patients undergoing native-valve TAVR between 2012 and 2015 based on anticoagulant use at hospital discharge.
Prosthetic leaflet thrombosis is a growing concern in transcatheter aortic valve replacement (TAVR). We analyzed patients undergoing native-valve TAVR between 2012 and 2015 based on anticoagulant use at hospital discharge.
Prosthetic leaflet thrombosis is...
10/23/2017
Journal of Invasive Cardiology
Original Contribution
10/31/2013

John P. Vavalle, MD,1 Thomas J. Povsic, MD, PhD,1 Laura H. Aberle, BSPH,1 Steven L. Zelenkofske, DO,2 Roxana Mehran, MD,3 Jaroslaw D. Kasprzak, MD,4 Christoph Bode, MD,5 Christopher E. Buller, MD,6 Gilles Montalescot, MD,7 Jan H. Cornel, MD,8 Richard C. Becker, MD,1 John H. Alexander, MD, MHS,1 Mauricio G. Cohen, MD9

John P. Vavalle, MD,1 Thomas J. Povsi...
Anticoagulation with REG1 allows for very early arterial sheath removal following cardiac catheterization without increasing the time to hemostasis or vascular access-site bleeding complications. Further studies are needed to determine...
Anticoagulation with REG1 allows for very early arterial sheath removal following cardiac catheterization without increasing the time to hemostasis or vascular access-site bleeding complications. Further studies are needed to determine...
Anticoagulation with REG1 allows...
10/31/2013
Journal of Invasive Cardiology